Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI

A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia

NCT06368414 ·Status: RECRUITING ·Phase: PHASE2

Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

NCT03045120 ·Status: COMPLETED

Study Conducted Among Patients With CML

NCT05476562 ·Status: COMPLETED

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

NCT07091019 ·Status: NOT_YET_RECRUITING

Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia

NCT03214718 ·Status: UNKNOWN ·Phase: NA

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

NCT03885830 ·Status: COMPLETED

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

NCT03106779 ·Status: COMPLETED ·Phase: PHASE3

Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy

NCT06692803 ·Status: COMPLETED

Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib

NCT02733445 ·Status: COMPLETED

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population

NCT04626024 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

NCT02326311 ·Status: COMPLETED ·Phase: PHASE3

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

NCT05367765 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

NCT04948333 ·Status: COMPLETED ·Phase: PHASE3

Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors

NCT01752062 ·Status: UNKNOWN

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

NCT01244750 ·Status: COMPLETED

The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients

NCT04933526 ·Status: UNKNOWN ·Phase: PHASE4

Withdrawal or Reduction TKIs in CML-CP

NCT04143087 ·Status: UNKNOWN

Biomarker Study of Chemotherapy Resistance and Outcomes in Samples From Older Patients With Acute Myeloid Leukemia

NCT01421875 ·Status: COMPLETED

Early Conversion of Dasatinib in CML-CP Patients

NCT04136015 ·Status: UNKNOWN

Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML

NCT06724536 ·Status: RECRUITING

A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan

NCT07150793 ·Status: COMPLETED

Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL

NCT06658925 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment

NCT07188428 ·Status: COMPLETED

Natural Killer Cells in Older Patients With Acute Myeloid Leukemia

NCT00540956 ·Status: COMPLETED ·Phase: NA